Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Haematologica
|
October 15, 2020
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Hannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
European Journal of Haematology
|
June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada
Donna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Ejhaem
|
June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database
Rayan Kaedbey, Donna Reece, Christopher P Venner, et al.
Ejhaem
|
December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Arleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
European Journal of Haematology
|
August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis
Richard LeBlanc, Hira Mian, Donna Reece, et al.
Blood
|
October 25, 2018
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J Bahlis, Heather Sutherland, Darrell White, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 14, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada
Hira S Mian, Alissa Visram, Steven Chun-Min Shih, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
Arleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia
|
May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
Martha L Louzada, Donna Reece, Christopher P Venner, et al.
Frontiers in Oncology
|
March 7, 2022
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Hira Mian, Christine Eisfeld, Christopher P Venner, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Haematologica
|
October 15, 2020
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Hannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
European Journal of Haematology
|
June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada
Donna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Ejhaem
|
June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database
Rayan Kaedbey, Donna Reece, Christopher P Venner, et al.
Ejhaem
|
December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Arleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
European Journal of Haematology
|
August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis
Richard LeBlanc, Hira Mian, Donna Reece, et al.
Blood
|
October 25, 2018
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J Bahlis, Heather Sutherland, Darrell White, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 14, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada
Hira S Mian, Alissa Visram, Steven Chun-Min Shih, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis
Arleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia
|
May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
Martha L Louzada, Donna Reece, Christopher P Venner, et al.
Frontiers in Oncology
|
March 7, 2022
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Hira Mian, Christine Eisfeld, Christopher P Venner, et al.
Page
of 7